**Core Concept**
Pneumocystis jirovecii pneumonia (PCP) is a life-threatening opportunistic infection in immunocompromised patients, particularly those with HIV/AIDS. Effective treatment requires a specific class of antimicrobial agents that target the causative organism.

**Why the Correct Answer is Right**
Cotrimoxazole, also known as trimethoprim-sulfamethoxazole (TMP-SMX), is the primary treatment for PCP. This combination drug works by inhibiting dihydrofolate reductase (DHFR) and dihydropteroate synthase enzymes in the bacterial pathway, thereby preventing the synthesis of tetrahydrofolate. This mechanism disrupts the essential processes of nucleic acid synthesis and cell replication in Pneumocystis jirovecii.

**Why Each Wrong Option is Incorrect**
**Option B:** Erythromycin is a macrolide antibiotic that targets protein synthesis in bacteria, which is not effective against Pneumocystis jirovecii.
**Option C:** Penicillin is a beta-lactam antibiotic that inhibits cell wall synthesis in susceptible bacteria, but it has no activity against Pneumocystis jirovecii.
**Option D:** Metronidazole is an antibiotic that targets anaerobic bacteria by disrupting DNA and protein synthesis, but it is not indicated for PCP.

**Clinical Pearl / High-Yield Fact**
Cotrimoxazole is a broad-spectrum antimicrobial agent that also exhibits synergistic activity against a range of other pathogens, including Toxoplasma gondii and some strains of E. coli. This dual-action mechanism makes it a valuable treatment option in various clinical contexts.

**✓ Correct Answer: A. Cotrimoxazole**